News | November 21, 2025
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
The investment in land is Rs. 19.85 crore
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Subscribe To Our Newsletter & Stay Updated
